Onxeo receives the EnterNext Tech 40 Label

Onxeo is admitted to the “Tech 40” index, which incorporates 40 outstanding small and midcap Tech companies listed on the various Euronext markets in Europe

Paris, April 20, 2017 – 8:30 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, has received the EnterNext Tech 40 Label and is thus admitted to the “Tech 40” index.

The “Tech 40” label is an initiative launched two years ago by Euronext to give more prominence to outstanding Tech companies listed on the various European markets covered by EnterNext (Amsterdam, Brussels, Lisbon and Paris).

The 40 companies receiving this label were chosen by a committee of independent European experts based on their business, financial and stock market performances.

More information on https://tech.euronext.com/en/our-tech-companies/all-tech-40-companies

170420_EN_Onxeo_Tech40